Omni Bio Pharmaceutical Inc (OMBP) financial statements (2021 and earlier)
Company profile
| Business Address |
181 W BOARDWALK DRIVE FORT COLLINS, CO 80525 |
| State of Incorp. | CO |
| Fiscal Year End | March 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2014 Q3 | 9/30/2014 Q2 | 6/30/2014 Q1 | 3/31/2014 Q4 | 12/31/2013 Q3 | 9/30/2013 Q2 | 6/30/2013 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 852 | 710 | 652 | 271 | 485 | 780 | 1,262 | ||
| Cash and cash equivalents | 852 | 710 | 652 | 271 | 485 | 780 | 1,262 | ||
| Other current assets | 70 | 111 | 142 | 32 | 69 | 106 | 128 | ||
| Total current assets: | 922 | 821 | 794 | 304 | 554 | 887 | 1,390 | ||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 60 | 61 | 62 | 63 | 65 | 66 | 67 | ||
| Intangible assets, net (excluding goodwill) | 60 | 61 | 62 | 63 | 65 | 66 | 67 | ||
| Regulated entity, other noncurrent assets | 104 | 130 | 156 | 192 | 219 | ||||
| Deferred costs | 51 | 77 | |||||||
| Total noncurrent assets: | 111 | 138 | 166 | 193 | 221 | 258 | 286 | ||
| TOTAL ASSETS: | 1,033 | 959 | 959 | 497 | 775 | 1,144 | 1,676 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 469 | 348 | 65 | 96 | 69 | 59 | 93 | ||
| Accounts payable | 1 | 9 | 13 | 5 | 11 | ||||
| Accrued liabilities | 151 | 81 | 53 | 88 | 56 | 54 | 82 | ||
| Interest and dividends payable | 319 | 267 | 11 | ||||||
| Debt | 206 | 345 | |||||||
| Other undisclosed current liabilities | 927 | 1,525 | 409 | ||||||
| Total current liabilities: | 1,603 | 2,218 | 473 | 96 | 69 | 59 | 93 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 254 | 282 | 255 | 277 | 251 | ||||
| Long-term debt, excluding current maturities | 254 | 282 | 255 | 277 | 251 | ||||
| Other undisclosed noncurrent liabilities | 2,253 | 601 | 1,214 | 1,003 | 913 | 1,001 | 1,053 | ||
| Total noncurrent liabilities: | 2,253 | 601 | 1,468 | 1,285 | 1,167 | 1,279 | 1,304 | ||
| Total liabilities: | 3,855 | 2,819 | 1,941 | 1,381 | 1,236 | 1,337 | 1,397 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (2,823) | (1,859) | (982) | (884) | (461) | (193) | 279 | ||
| Common stock | 40 | 39 | 39 | 39 | 39 | 38 | 38 | ||
| Additional paid in capital | 46,891 | 46,457 | 46,345 | 45,609 | 45,592 | 45,105 | 44,937 | ||
| Other undisclosed stockholders' equity attributable to parent | (49,754) | (48,355) | (47,365) | (46,532) | (46,091) | (45,336) | (44,696) | ||
| Other undisclosed stockholders' equity | 0 | ||||||||
| Total stockholders' equity: | (2,823) | (1,859) | (982) | (884) | (461) | (193) | 279 | ||
| TOTAL LIABILITIES AND EQUITY: | 1,033 | 959 | 959 | 497 | 775 | 1,144 | 1,676 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2014 Q3 | 9/30/2014 Q2 | 6/30/2014 Q1 | 3/31/2014 Q4 | 12/31/2013 Q3 | 9/30/2013 Q2 | 6/30/2013 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (522) | (614) | (533) | (297) | (446) | (638) | (531) | |
| Operating loss: | (522) | (614) | (533) | (297) | (446) | (638) | (531) | |
| Nonoperating expense | (877) | (376) | (300) | (144) | (309) | (2) | (150) | |
| Investment income, nonoperating | (44) | 39 | (5) | |||||
| Interest and debt expense | (134) | (28) | (28) | |||||
| Net loss: | (1,533) | (990) | (834) | (440) | (783) | (668) | (681) | |
| Other undisclosed net income attributable to parent | 134 | 28 | 28 | |||||
| Net loss available to common stockholders, diluted: | (1,399) | (990) | (834) | (440) | (755) | (640) | (681) | |
Comprehensive Income ($ in thousands)
| 12/31/2014 Q3 | 9/30/2014 Q2 | 6/30/2014 Q1 | 3/31/2014 Q4 | 12/31/2013 Q3 | 9/30/2013 Q2 | 6/30/2013 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (1,533) | (990) | (834) | (440) | (783) | (668) | (681) | |
| Comprehensive loss, net of tax, attributable to parent: | (1,533) | (990) | (834) | (440) | (783) | (668) | (681) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.